Skip to main content
. 2023 Sep 28;12:84. doi: 10.1186/s40164-023-00442-x

Table 3.

Clinical trials of gut microbiome as biomarker of immunotherapy

Type Conditions Interventions Phases Enrollment Funder type Start date Completion date Locations Study status NCT number
Response Gastric cancer, stomach neoplasm JS001 + chemotherapy (XELOX or SOX) Phase2 110 Other 2021/3/12 2024/12/30 China Recruiting NCT04744649
Response ESCC Sintilimab + chemotherapy 30 Other 2021/12/1 2023/6/1 China Recruiting NCT05199649
Response Colorectal adenocarcinoma Fruquintinib + PD-1 inhibitors; fruquintinib + PD-1 inhibitors + radiotherapy 100 Other 2022/1/1 2023/9/30 China Recruiting NCT05635149
Response CRC CAP + pembrolizumab + bevacizumab 50 Other 2018/4/13 2022/6/30 US Completed NCT04054908
Response Upper GI cancer Immunotherapy 40 Other 2021/10/1 2023/12/1 China Recruiting NCT05065515
Response Metastatic carcinoma, CRC Chemotherapy/immunotherapy 21 Other 2016/10/20 2022/4/13 US Terminated NCT02960282
Response NSCLC PD-1/PD-L1 inhibitors 50 Other 2021/8/12 2022/12/30 China Recruiting NCT04682327
Response Metastatic NSCLC ICI; ICI + chemotherapy 24 Other 2021/5/3 2025/11/1 France Active not recruiting NCT04804137
Response NSCLC, CRC, TNBC, pancreas cancer Immunotherapy; chemotherapy 5000 Industry 2022/7/1 2025/12/31 US Recruiting NCT04638751
Response NSCLC, malignant melanoma, RCC, TNBC ICI 800 Industry 2021/11/22 2028/9/14 US Recruiting NCT05037825
Response Carcinoma Pembrolizumab 100 Industry 2019/6/28 2022/12/31 US Unknown NCT04291755
Response Melanoma ICI 450 Other_gov 2018/4/4 2023/5/2 UK Unknown NCT03643289
Response Urothelial carcinoma Atezolizumab; pembrolizumab 40 Other 2020/12/2 2023/6/1 France Recruiting NCT04566029
Response Advanced cancer ICI 150 Other 2016/11/29 2024/9/1 US Recruiting NCT04204434
Response Diffuse large B cell lymphoma Chemo-immunotherapy 50 Other 2019/4/2 2023/12/20 Italy Active not recruiting NCT03797170
Response Gynecologic cancer Immunotherapy 30 Industry 2021/6/29 2023/6/1 US Recruiting NCT04957511
Response Melanoma Pembrolizumab; lenvatinib Phase2 44 Other 2023/5/1 2030/10/1 Australia Not yet recruiting NCT05545969
Response Solid carcinoma Immunotherapy 60 Other 2018/6/4 2023/4/30 Korea Unknown NCT04264975
Response and irAEs Melanoma, renal cancer, lung cancer Nivolumab; pembrolizumab; ipilimumab; durvalumab; tremelimumab; atezolizumab; bevacizumab 1800 Other 2020/7/8 2025/7/8 UK Recruiting NCT04107168
Response and irAEs Non-squamous NSCLC Pembrolizumab; pembrolizumab + pemetrexed + carboplatin 150 Other 2021/5/18 2024/12/31 US Recruiting NCT04954885
Response and irAEs Advanced solid tumor ICI 60 Other 2018/4/1 2024/12/1 Canada Recruiting NCT04579978
Response and irAEs Lung cancer ICI 44 Other 2018/8/30 2022/5/9 US Completed NCT03688347
irAEs Melanoma Ipilimumab; nivolumab; pembrolizumab 123 Other 2013/8/1 2019/4/1 Netherlands Completed NCT02600143
irAEs NSCLC ICI 150 Other 2021/1/21 2023/3/3 US Recruiting NCT04913311

US United States, UK United Kingdom, GI gastrointestinal, ESCC esophageal squamous cell carcinoma, NSCLC non-small cell lung cancer, TNBC triple negative breast cancer, CRC colorectal cancer, CAP capecitabine, RCC renal cell carcinoma, ICI immune checkpoint inhibitor